Dizal Pharmaceuticals
Clinical trials sponsored by Dizal Pharmaceuticals, explained in plain language.
-
New pill takes on chemo for rare lung cancer mutation
Disease control OngoingThis study compares a new oral targeted therapy (DZD9008) to standard chemotherapy in people with advanced non-small cell lung cancer that has a specific genetic change (EGFR exon20 insertion). About 324 participants who have not had prior treatment will be randomly assigned to r…
Phase: PHASE3 • Sponsor: Dizal Pharmaceuticals • Aim: Disease control
Last updated May 12, 2026 13:42 UTC
-
New hope for Hard-to-Treat lung cancer: targeted drug shows promise in early trial
Disease control OngoingThis study tests a new drug called DZD9008 (sunvozertinib) in people with advanced non-small cell lung cancer that has specific gene changes (EGFR or HER2 mutations) and has stopped responding to other treatments. The goal is to check the drug's safety, side effects, and how well…
Phase: PHASE1, PHASE2 • Sponsor: Dizal Pharmaceuticals • Aim: Disease control
Last updated May 11, 2026 20:40 UTC
-
New hope for Tough-to-Treat lymphoma: experimental drug DZD8586 under study
Disease control OngoingThis study tests an experimental drug called DZD8586 in 59 adults with diffuse large B-cell lymphoma that has returned or stopped responding to prior treatments. The goal is to see if the drug can shrink tumors and to understand its side effects and how the body processes it. Par…
Phase: PHASE2 • Sponsor: Dizal Pharmaceuticals • Aim: Disease control
Last updated May 05, 2026 11:56 UTC